Skip to content
homeHOME R&D Mission & Vison R&D Pipeline

R&D Pipeline

YRI enhances success rates and maintains an innovative drug pipeline by adopting a strategy that focuses on critical areas of unmet medical need. Currently, the main areas of focus include cardiovascular and metabolic diseases, inflammatory and immune disorders, and cancer. YRI continually enriches its competitive drug pipeline by establishing collaborative partnerships with academic research centers, bio-ventures, and government-funded research institutes worldwide. A strong development pipeline further strengthens YRI’s global outreach capacity by expanding potential licensing agreements.

Gastrointestinal Disorder

Gastrointestinal Disorder
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH12852 Postoperative ileus
Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2

Cardiometabolic Disorder

Cardiometabolic Disorder
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH-NCE10 Gaucher disease, Fabry disease, Parkinson disease
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE9 Non-alcoholic steatohepatitis
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO4 Obesity
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH1604 Hypertension/Hyperlipidemia
YH1701 Hypertension/Hyperlipidemia
YH14755 Hyperlipidemia/Diabetes
YH25724 Non-alcoholic steatohepatitis
PreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinical
YH-NCE5 Non-alcoholic steatohepatitis
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE6 Non-alcoholic steatohepatitis
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery

Cardiovascular Disorder

Cardiovascular Disorder
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH22162 Hypertension

Immunology / Inflammation

Immunology / Inflammation
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH1713 Rhematoid arthritis
Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1
YH14618 Degenerative disc disease
Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2
YH-NCE1 Asthma
PreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinical
YH-siRNA1 Keloid
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery

Oncology

Oncology
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH-BIO9 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO8 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO7 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO6 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO5 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO4 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH25248 Immuno-oncology
PreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinical
Lazertinib (YH25448) Lung cancer
Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3
YH24931 Immuno-oncology
Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1
YH-NCE2 Liver cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE3 Lung cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE4 RCC
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE7 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH29143 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO2 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO3 Immuno-oncology
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-siRNA2 Liver cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery

Others

Others
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YHD1119 Neuropathic pain